Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1997-05-23
2000-08-29
Brusca, John S.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
435 6, 435 691, 435 911, 435455, 424 931, 4242041, 4242341, 4242561, A61K 4800, C17N 1500, C12Q 170
Patent
active
061108987
ABSTRACT:
The invention consists of a method for inducing production of a mucosal immune response in a host by administration of an antigen-encoding polynucleotide preparation, comprising DNA or RNA encoding an antigenic epitope to a mucosal inductor site in the mucosal tissue of the host. Naked DNA may be administered directly to mucosa, for instance in saline drops, or in a recombinant gene expression vector. Preferably, the recombinant gene expression vectors are not capable of replication or dessimination. The invention also includes the use of live viral vaccines wherein the viruses include immunostimulatory polynucleotides of the invention. According to a preferred method of the invention, a target protein antigen is administered through its expression by a recombinant gene expression vector.
REFERENCES:
patent: 5589466 (1996-12-01), Felgner et al.
patent: 5593972 (1997-01-01), Weiner et al.
patent: 5703055 (1997-12-01), Felgner et al.
Kiyono, H., et al. "The Common Mucosal Immune System for the Reproductive Tract: Basic Principles Applied toward an AIDS Vaccine" Adv. Drug Del. Rev. 18:23-51, 1995.
Miller, C.J., et al. "Rhesus Macaques Previously Infected with Simian/Human Immunodeficiency Virus Are Protected from Vaginal Challenge with Pathogenic SIVmac239" J. Virol. 71:1911-1921, 1997.
Gallichan, W. S., et al. "Mucosal Immunization with a Recombinant Adenovirus Vector Induces Local and Systemic Immunity and Protection from Herpes Simplex Virus" Adv. in Mucosal Immun. 1581-1585, 1995.
Anderson, M.J., et al. "Characterization of the Expression and Immunogenicity of Poliovirus Replicons that Encode Simian Immunodeficiency Virus SIV.sub.mac 239 Gag or Envelope SU Proteins" AIDS Res. Hum Retroviruses 13:53-62, 1997.
Sabbaj, S., et al. "Mucosal Immunisation for Enteric Diseases" BioDrugs, 2:134-157, Adis International Ltd., 1997.
Bassler, K.D., et al. "Genetic Immunization: Effects of Novel Priming and Boosting Strategies" New Approaches to Vaccine Development, Vienna, Apr. 1995.
Malone, R.W., et al. "Mucosal Immune Responses Associated with Polynucleotide Vaccination" New Approaches to Bacterial Vaccine Development, Munich, Germany, May 1996.
Malone, J.G., et al. "Mucosal Immune Responses Associated with Polynucleotide Vaccination" Behring Inst. Mitt. 98:1-10, 1996.
Ulmer, J.B., et al. "Prospects for Induction of Mucosal Immunity by DNA Vaccines" Mucosal Vaccines 8:119-127, Academic Press Inc., 1996.
Kuklin, N., et al. "Induction of Mucosal Immunity against Herpes Simplex Virus by Plasmid DNA Immunization" J. Virol. 71:3138-3145, 1997.
Dixon, B., "The Third Vaccine Revolution" cmt Bio/Technology 13:420, 1995.
Robbins-Roth, C., Ed. "Cancer Vaccines: Are We Finally on the Right Track?" Bioventure View Oct. 12, 1997.
Haynes et al. "Scientific and Social Issues of Human Immunodeficiency Virus Vaccine Development" Science vol. 260:1279-1286, May 28, 1993.
Verma et al. "GeneTherapy--Problems and Prospects" Nature vol. 389:239-242, Sep. 18, 1997.
Malone Jill G.
Malone Robert W.
Brusca John S.
McGarry Sean
University of Maryland Baltimore
LandOfFree
DNA vaccines for eliciting a mucosal immune response does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with DNA vaccines for eliciting a mucosal immune response, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and DNA vaccines for eliciting a mucosal immune response will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1249969